Renal Impairment Study

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see how quickly AZD3355 is taken up in to the blood and leaves the blood in people with normal kidney function or with different degrees of reduced kidney function.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Lesogaberan

Criteria

Inclusion Criteria:

• Provision of signed informed consent

• Subjects should have either normal renal function or have a moderate renal impairment or severe renal impairment

Exclusion Criteria:

• History of heart disease

• Unstable or clinically significant other disorders such as respiratory, hepatic, metabolic, psychiatric or gastrointestinal disorder